Puma Biotechnology, Inc.
- PBYI
- NASDAQ
- Biotechnology
- Cancer Drugs (Neratinib)
- Oncology Therapeutics
$9.83
Today −6.56%Quote Oct 16, 2026, 08:00 PM UTC
+3.26%over the last month
Max drawdown −6.6%From 1-month high −6.6%3 months +18.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$507.4M
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Latest analyst target
—
Data unavailable
Floor
$9.63
2.1% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PBYIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $56.5M
- Product$53.6M94.8%
- Royalty$2.9M5.2%
Industry
Biotechnology
Employees
179